The United States-Mexico-Canada Agreement (USMCA) benefits American manufactures as well as the overall economy. Please join our letter thanking the Administration for their work on this historic trade deal. Click here to read the full text of the letter follows, and you can add your organization by filling out the form. ...
CyByte, a software development company, is pleased to announce their investment in VideoKall, a telehealth provider.
VideoKall is a telemedicine platform provider and operator specializing in enabling medical providers to offer healthcare services to patients in micro-clinic booths at convenient locations, wherever they live, work, travel, go to school or shop.
Neeraj Chitra, CEO of CyByte, said “this is an exciting time in healthcare, and CyByte is appreciative of VideoKall for combining our expertise with their innovative approach to better access and lower cost services.” The new software platform for VideoKall includes the major portions for the medical devices and subsystems in the CLINICSTOP® booth, but also the broadband videophone telecommunications, the call center equipment, the medical terminals and a new patient engagement mobile app. CyByte’s on-demand expertise has completed its first phase where recent tests confirmed that the desired outcomes are predictable and build off the lessons learned from VideoKall’s patented working prototype and the healthcare software expertise of CyByte. ...
Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations ...
ROCKVILLE, MD, September 14, 2018
Creatv MicroTech, Inc. (Creatv) has received a $625,000 award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to investigate their discovery of giant circulating cells found in peripheral blood for non-invasive detection of lung cancer by differentiating malignant from benign pulmonary nodules detected by low dose CT (LDCT). In the three-year study, Creatv will examine blood samples from 1,250 subjects at high risk for lung cancer based on their smoking history and occupational exposure to carcinogens. ...
GERMANTOWN, Md., Sept. 5, 2018 /PRNewswire/ — SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes. ...
Tech Entrepreneurs Outgrow Incubator, Welcome Room to Grow ...
FREDERICK, Md., Aug. 31, 2018 /PRNewswire-PRWeb/ — Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). ...
CHICAGO, Aug. 14, 2018 /PRNewswire/ — Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age. ...
The BIO Investor Forum delivers a rich program that features corporate presentations and panel debates on the sweet spots and growth challenges facing the industry. The BIO Investor Forum features: ...
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QMing. There was a Series A round worth $11 million. ...